Introducing testosterone replacement or therapy for advanced PC patients is a tricky and risky undertaking. This has been much discussed in this forum. Perhaps it has a place for some specific men with mCRPC who become unresponsive to other treatments and are willing to risk accelerating their cancer. Perhaps the most likely scenario are those on intermittent ADT regimens who do not spontaneously recover normal testosterone function in a timely manner, and are functionally not really getting an ADT "vacation". Others (myself included) have severe hypogonadal symptoms and sarcopenia from ADT and are willing to risk accelerating indolent PC in order to benefit from some form of cyclic testosterone. This must be a carefully considered personal decision that is not SOC. Further research is ongoing to clarify for whom BAT or cyclic TRT might be reasonable or appropriate.
The following article shows surprisingly profound effects of BAT to improve body composition and Quality-of-Life. Perhaps not so surprising after all.
bjui-journals.onlinelibrary...
Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer
Catherine H. Marshall, Jessa Tunacao, Varun Danda, Hua-Ling Tsai, John Barber, …
First published: 25 March 2021 doi.org/10.1111/bju.15408
Abstract
To investigate whether bipolar androgen therapy (BAT), involving rapid cyclic administration of high-dose testosterone, as a novel treatment for metastatic castration-resistant prostate cancer (mCRPC) promotes improvements in body composition and associated improvements in lipid profiles and quality of life.
Patients and Methods
Men from two completed trials with computed tomography imaging at baseline and after three cycles of BAT were included. Cross-sectional areas of psoas muscle, visceral and subcutaneous fat were measured at the L3 vertebral level. Functional Assessment of Chronic Illness Therapy – Fatigue questionnaire and 36-item short-form health survey were used to assess quality of life.
Results
The 60 included patients lost a mean (sd) of 7.8 (8.2)% of subcutaneous fat, 9.8 (18.2)% of visceral fat, and gained 12.2 (6.7)% muscle mass. Changes in subcutaneous and visceral fat were positively correlated with each other (Spearman’s correlation coefficient 0.58, 95% confidence interval 0.35–0.71) independent of the effects of age, body mass index, and duration of androgen-deprivation therapy. Energy, physical function, and measures of limitations due to physical health were all significantly improved at 3 months. The improvements in body composition were not correlated with decreases in lipid levels or observed improvements in quality of life.
Conclusions
In the present study, BAT was associated with significant improvements in body composition, lipid parameters, and quality of life. This has promising implications for the long-term health of men with mCRPC.